Clinical trial
A Multicenter, Prospective, Randomized Controlled Modified Platform Trial Assessing the Efficacy of Human Placental Membrane Products and Standard of Care Versus Standard of Care Alone in the Management of Nonhealing Diabetic Foot Ulcers and Venous Leg Ulcers.
NCT06674980 is registered in ClinicalTrials.gov with C5 Biomedical as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Multicenter, Prospective, Randomized Controlled Modified Platform Trial Assessing the Efficacy of Human Placental Membrane Products and Standard of Care Versus Standard of Care Alone in the Management of Nonhealing Diabetic Foot Ulcers and Venous Leg Ulcers.
- Lead sponsor
- C5 Biomedical
- Phase
- Not applicable
- Overall status
- Recruiting
- Start date
- December 20, 2024
- Completion date
- January 22, 2027
- Enrollment
- 177 (estimated)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.
cardiovascular diseases, diabetes complications, diabetes mellitus, diabetes mellitus, type 2, diabetic angiopathies, diabetic foot, diabetic neuropathies, endocrine system disease, foot diseases, foot ulcer, foot ulcer unhealed, glucose metabolism disorders, leg ulcer, metabolic diseases, pathologic processes, skin diseases, skin ulcer, ulcer, vascular diseases